Daiichi Sankyo is planning to buy Indian companies and is in talks with at least three mid-sized firms in India according to ET.
Daiichi Sankyo is focusing primarily on firms with an annual turnover of R300-500Cr with a product portfolio including straddling anti-diabetes, rheumatology and woman's healthcare.
In 2008, Daiichi acquired 60% stake in 
Ranbaxy Laboratories for $4.6 bn. Daiichi had to write off $500 Mn from its books due to the Ranbaxy settlement. It posted a loss of $255 Mn in the third quarter.
In 2008, the FDA banned 30 drugs made at Ranbaxy's plants in Dewas and Poanta Sahib and stopped approving new ones for violating US drug manufacturing rules.
In December last year, Ranbaxy reached an agreement with the US health regulator to lift a ban on the import of drugs from certain factories in India, a move which could see the drug-maker pay up to $ 500 Mn as fine to the American authorities.
Recently, Strides Arcolab Limited has sold 94% stake in subsidiary – Ascent Pharmahealth Limited with operations in Austria and Southeast Asia to Watson Pharmaceuticals Inc for an enterprise value of AU$375 Mn; while Dishman Pharmaceuticals & Chemicals Ltd has acquired France based contract development firm - Creapharm Parenterals through it's wholly owned subsidiary - Carbogen Amcis AG.
| |
4134
3846
945
4260
973
|
|
17649
42
1677
25526
3005
|
|
1369
459
3151
32715
140
|
|
24632
|
|
